Article (Scientific journals)
Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe.
Jerusalem, Guy; Neven, Patrick; Marinsek, Nina et al.
2015In BMC Cancer, 15, p. 787
Peer Reviewed verified by ORBi
 

Files


Full Text
Pattern of resource utilization and cost for postmenopausal ....pdf
Publisher postprint (849.29 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
oncology
Abstract :
[en] BACKGROUND: Healthcare resource utilization in breast cancer varies by disease characteristics and treatment choices. However, lack of clarity in guidelines can result in varied interpretation and heterogeneous treatment management and costs. In Europe, the extent of this variability is unclear. Therefore, evaluation of chemotherapy use and costs versus hormone therapy across Europe is needed. METHODS: This retrospective chart review (N = 355) examined primarily direct costs for chemotherapy versus hormone therapy in postmenopausal women with hormone-receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer across 5 European countries (France, Germany, The Netherlands, Belgium, and Sweden). RESULTS: Total direct costs across the first 3 treatment lines were approximately euro10 000 to euro14 000 lower for an additional line of hormone therapy-based treatment versus switching to chemotherapy-based treatment. Direct cost difference between chemotherapy-based and hormone therapy-based regimens was approximately euro1900 to euro2500 per month. Chemotherapy-based regimens were associated with increased resource utilization (managing side effects; concomitant targeted therapy use; and increased frequencies of hospitalizations, provider visits, and monitoring tests). The proportion of patients taking sick leave doubled after switching from hormone therapy to chemotherapy. CONCLUSIONS: These results suggest chemotherapy is associated with increased direct costs and potentially with increased indirect costs (lower productivity of working patients) versus hormone therapy in HR+, HER2- advanced breast cancer.
Disciplines :
Oncology
Author, co-author :
Jerusalem, Guy  ;  Université de Liège - ULiège
Neven, Patrick
Marinsek, Nina
Zhang, Jie
Degun, Ravi
Benelli, Giancarlo
Saletan, Stephen
Ricci, Jean-Francois
Andre, Fabrice
Language :
English
Title :
Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe.
Publication date :
2015
Journal title :
BMC Cancer
eISSN :
1471-2407
Publisher :
BioMed Central, London, United Kingdom
Volume :
15
Pages :
787
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 09 December 2015

Statistics


Number of views
87 (3 by ULiège)
Number of downloads
107 (4 by ULiège)

Scopus citations®
 
6
Scopus citations®
without self-citations
6
OpenCitations
 
5

Bibliography


Similar publications



Contact ORBi